Treatment of Ebola virus disease

Intensive Care Medicine

Volumn 41, Issue 1, 2015, Pages 115-117

  Yazdanpanah, Yazdan ^a,b   Arribas, Jose Ramon ^c   Malvy, Denis ^d,e  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BCX 4430; BRINCIDOFOVIR; FAVIPIRAVIR; IMMUNOGLOBULIN; INFUSION FLUID; MONOCLONAL ANTIBODY; NUCLEOSIDE ANALOG; UNCLASSIFIED DRUG; VACCINE;

ANTIBIOTIC THERAPY; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CAUSE OF DEATH; COMPASSIONATE USE; CONVALESCENCE; CYTOKINE RELEASE; DIARRHEA; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; ELECTROLYTE DISTURBANCE; EPIDEMIC; EVIDENCE BASED PRACTICE; EXPERIMENTAL THERAPY; FILOVIRUS; GASTROINTESTINAL SYMPTOM; HEALTH CARE PERSONNEL; HUMAN; IMMUNOTHERAPY; INFECTION CONTROL; INFLUENZA; MALARIA; MARBURG VIRUS; NONHUMAN; ORAL REHYDRATION THERAPY; RNA INTERFERENCE; SHOCK; VOMITING; FLUID THERAPY; HEMORRHAGIC FEVER, EBOLA; ORGANIZATION AND MANAGEMENT;

ANTIVIRAL AGENTS; COMMUNICABLE DISEASE CONTROL; DISEASE OUTBREAKS; FLUID THERAPY; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNOTHERAPY;

EID: 84918531687     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-014-3529-8     Document Type: Article

References (15)

1. WHO. Ebola response roadmap update (17 October 2014) [Internet]. 2014. Available from: http://apps.who.int/iris/bitstream/10665/136645/1/roadmapupdate17Oct14_eng.pdf?ua=1. Cited 20 Oct 2014
2. WHO Ebola Response Team (2014) Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections. N Engl J Med 371(16):1481–1495
3. Fowler RA, Fletcher T, Fischer WA, Lamontagne F, Jacob S, Brett-Major D et al (2014) Caring for critically ill patients with Ebola virus disease. Perspectives from west Africa. Am J Respir Crit Care Med 190(7):733–737
4. Gulland A (2014) First Ebola treatment is approved by WHO. BMJ 349:g5539
5. WHO Blood Regulators Network (BRN) (2014) Position paper on collection and use of convalescent plasma or serum as an element in filovirus outbreak response. WHO, Geneva
6. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE et al (2012) Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 109(13):5034–5039
7. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M et al (1999) Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 179(Suppl 1):S18–S23
8. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB et al (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514(7520):47–53
9. Geisbert TW, Lee ACH, Robbins M, Geisbert JB, Honko AN, Sood V et al (2010) Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375(9729):1896–1905
10. Maurice J (2014) WHO meeting chooses untried interventions to defeat Ebola. Lancet 384(9948):e45–e46
11. Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S (2014) Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antivir Res 105:17–21
12. Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults [Internet]. Available from: http://www.clinicaltrials.gov/show/NCT02008344. Cited 7 Oct 2014
13. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA et al (2014) Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508(7496):402–405
14. Joffe S (2014) Evaluating novel therapies during the Ebola epidemic. JAMA 312(13):1299–1300
15. Goodman JL (2014) Studying “secret serums”—toward safe, effective Ebola treatments. N Engl J Med 371(12):1086–1089